The Jenex Corporation announces private placement



    BURLINGTON, ON, March 13 /CNW/ - The Jenex Corporation ("Jenex" or the
"Corporation") (TSX Venture Exchange: JEN, Frankfurt: JNX) announced today
that it is proposing to complete, subject to regulatory approval, a
non-brokered private placement of up to 1,130,000 units at a price of $0.27
cents per unit to raise up to $305,100. Each unit will consist of one common
share of the corporation and one half of a non-transferable share purchase
warrant at $0.40 (up to 565,000 whole warrants in total). Each whole warrant
will entitle the holder thereof to purchase one additional common share of the
corporation at a price of .40 cents per common share for a period of one year
following the closing date of the private placement. In connection with the
foregoing, the corporation proposes to pay a finder's fee to its agent,
Kingsdale Capital Markets Inc., of up to $24,408 in cash and 56,500 warrants
on the same terms as the warrants issued to investors.
    The transaction is subject to TSX Venture Exchange approval and the
shares and warrants will be subject to a four month hold period from the date
of issue.

    About Kingsdale Capital

    Kingsdale Capital is a leading global financial services organization and
more information about Kingsdale can be found at www.kingsdalecapital.com

    About The Jenex Corporation

    The Jenex Corporation owns a patented Thermal Therapy technology. The
first device developed from this technology is the Therapik(R) product, for
relief of pain and itch caused by insect stings and bites. Therapik(R) has
been approved as a Class II medical device in Canada (TPD) and the United
States (FDA), and has received CE approval in Europe. The second device,
interceptCS is the first product clinically proven and approved (TPD) to
prevent cold sores. interceptCS is available exclusively in Canada at Shoppers
Drug Mart/Pharmaprix. More information about the Corporation can be found at
www.jenexcorp.com & www.interceptCS.com .

    
                         "Prevention is the Solution"
    

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the accuracy or the contents of this press release.
    Certain information included in this press release is forward-looking and
    is subject to important risks and uncertainties. The results or events
    predicted in these statements may differ materially from actual results
    or events.

    %SEDAR: 00016201E




For further information:

For further information: Direct Inquiries to: The Jenex Corporation, 207
- 940 Sheldon Court, Burlington, Ontario, L7L 5K6, Michael A. Jenkins,
Telephone: (905) 632-3830, Facsimile: (905) 632-3774, Email:
jenex@jenexcorp.com, Website: www.jenexcorp.com

Organization Profile

THE JENEX CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890